AYTU BIOPHARMA, INC (AYTU)

Healthcare · Pharmaceuticals · Price $2.29
Updated: Sep 1, 2026
Revenue (TTM)
$56.6M
Trailing 12 Months
Growth Rate
-19.31%
Log-Linear Regression (16Q)
Price/Sales
0.4x
Valuation Multiple
Revenue Per Share
$5.38
Sales / Shares
Gross Margin
64.78%
Pricing Power

📈 Revenue History (16 Quarters)

🧮 AYTU Revenue Breakdown

Revenue = Product Sales + Service Revenue + Other Income
Total Revenue (TTM) $56.6M
Less: Cost of Revenue $19.9M
Equals: Gross Profit $36.7M
Then: Operating Income $-15.2M
Finally: Net Income $-34.1M

Understanding Revenue

Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For AYTU, the trailing twelve month revenue is $56.6M.

Why Revenue Matters

Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.

AYTU's revenue growth rate of -19.31% (based on log-linear regression of 16 quarters) indicates significant revenue decline, which requires investigation.

Revenue vs Profitability Metrics

Free Cash Flow: $-2.2M →

The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.

Owner Earnings: N/A →

Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.

Earnings Per Share: $-1.45 →

Net income per share. The bottom line result of all revenue after costs, taxes, and interest.

Net Income: $-34.1M

What remains after all expenses. Net margin shows what percentage of revenue becomes profit.

Price/Sales Ratio Analysis

AYTU's P/S ratio of 0.4x means investors pay $0.43 for every $1 of annual revenue. A P/S below 1 is generally considered "deep value" territory.

Gross Margin: Revenue Quality

Gross margin of 64.78% shows how much of AYTU's revenue remains after direct costs. High gross margins above 60% often indicate strong pricing power, brand value, or intellectual property moats.

Summary: AYTU Revenue Trend

AYTU BIOPHARMA, INC (AYTU) generated $56.6M in trailing twelve-month revenue, growing at -19.31% annually — a material decline Zyberno treats as a concern requiring investigation. AYTU BIOPHARMA, INC's gross margin of 64.78% is excellent for a Healthcare company — above the 60% threshold Zyberno applies to healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins, a level typically associated with strong pricing power and durable competitive advantages. For complete financial analysis, view the full AYTU stock report on Zyberno.

Frequently Asked Questions

What is AYTU's current revenue?

AYTU BIOPHARMA, INC's trailing twelve month (TTM) revenue is $56.6M, growing at -19.31% annually — a material decline Zyberno treats as a concern requiring investigation.

Is AYTU's revenue growing?

AYTU BIOPHARMA, INC (AYTU) generated $56.6M in trailing twelve-month revenue, growing at -19.31% annually — a material decline Zyberno treats as a concern requiring investigation. AYTU BIOPHARMA, INC's gross margin of 64.78% is excellent for a Healthcare company — above the 60% threshold Zyberno applies to healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins, a level typically associated with strong pricing power and durable competitive advantages.

What is AYTU's gross margin?

AYTU BIOPHARMA, INC's gross margin of 64.78% is excellent for a Healthcare company — above the 60% threshold Zyberno applies to healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins, a level typically associated with strong pricing power and durable competitive advantages.

What is AYTU's Price/Sales ratio?

AYTU's P/S ratio is 0.4x, meaning the market values the company at 0.4 times its annual revenue.

How does revenue differ from profit?

Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. AYTU's revenue is $56.6M with a net income of $-34.1M, showing a net profit margin of -60.2%.

📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
🛡️
Margin of Safety
Valuation Gap
🎯
Expected Return
Projected Annual
Click any metric for full methodology and detailed analysis

📊 Full AYTU Stock Report

See AYTU's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

💵 AYTU Free Cash Flow

Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.

💰 AYTU Owner Earnings

Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.

📈 AYTU Earnings Per Share

Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.

🎯 AYTU Earnings Surprise (SUE)

See whether AYTU is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

📊 AYTU Revenue

Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.

💰 AYTU Net Income

Analyze the bottom-line profit, P/E ratio, and net profit margin trends.

🔶 AYTU Operating Income

Analyze EBIT, operating margin, and core business profitability before interest and taxes.

💜 AYTU Gross Profit

Analyze gross margin, pricing power, and profitability before operating expenses.

View Full AYTU Report Find More Quality Stocks
Scroll to Top